151 related articles for article (PubMed ID: 7503660)
1. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group.
Grignon DJ; Hammond EH
Arch Pathol Lab Med; 1995 Dec; 119(12):1122-6. PubMed ID: 7503660
[TBL] [Abstract][Full Text] [Related]
2. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Colorectal Cancer Working Group.
Fielding LP; Pettigrew N
Arch Pathol Lab Med; 1995 Dec; 119(12):1115-21. PubMed ID: 7503659
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer.
Bostwick DG; Foster CS
Semin Urol Oncol; 1999 Nov; 17(4):222-72. PubMed ID: 10632123
[TBL] [Abstract][Full Text] [Related]
4. The TNM system of 1992. Comments from the TNM working group. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Chisholm GD; Hedlund PO; Adolfsson J; Denis LJ; Friberg S; Johansson JE; Peeling B
Scand J Urol Nephrol Suppl; 1994; 162():107-14; discussion 115-27. PubMed ID: 7529428
[TBL] [Abstract][Full Text] [Related]
5. Prognostic markers in prostate cancer.
Ross JS; Sheehan CE; Fisher HA; Kauffman RA; Dolen EM; Kallakury BV
Expert Rev Mol Diagn; 2002 Mar; 2(2):129-42. PubMed ID: 11962333
[TBL] [Abstract][Full Text] [Related]
6. College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Summary. Members of the Cancer Committee.
Henson DE; Fielding LP; Grignon DJ; Page DL; Hammond ME; Nash G; Pettigrew NM; Gorstein F; Hutter RV
Arch Pathol Lab Med; 1995 Dec; 119(12):1109-12. PubMed ID: 7503658
[No Abstract] [Full Text] [Related]
7. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
8. p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer.
Papadopoulos I; Rudolph P; Wirth B; Weichert-Jacobsen K
Urology; 1996 Aug; 48(2):261-8. PubMed ID: 8753738
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Schröder F; Tribukait B; Böcking A; DeVere White R; Koss L; Lieber M; Stenkvist B; Zetterberg A
Scand J Urol Nephrol Suppl; 1994; 162():51-63; discussion 15-27. PubMed ID: 7529429
[TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
11. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL
Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens.
Amin M; Boccon-Gibod L; Egevad L; Epstein JI; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Srigley JR; Wheeler TM; Montironi R
Scand J Urol Nephrol Suppl; 2005 May; (216):20-33. PubMed ID: 16019757
[TBL] [Abstract][Full Text] [Related]
13. Tumour serum markers: clinical and economical aspects.
Kardamakis D
Anticancer Res; 1996; 16(4B):2285-8. PubMed ID: 8694557
[TBL] [Abstract][Full Text] [Related]
14. Prognostic markers in clinically localized prostate cancer.
Pettaway CA
Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens.
Epstein JI; Amin M; Boccon-Gibod L; Egevad L; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Srigley JR; Wheeler TM; Montironi R
Scand J Urol Nephrol Suppl; 2005 May; (216):34-63. PubMed ID: 16019758
[TBL] [Abstract][Full Text] [Related]
16. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer: indicators of aggressiveness.
Sakr WA; Grignon DJ
Eur Urol; 1997; 32 Suppl 3():15-23. PubMed ID: 9267782
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age.
Shockley KF; Maatman TJ; Carothers GC; Warzynski MJ
Prostate; 1996 Jul; 29(1):46-50. PubMed ID: 8685055
[TBL] [Abstract][Full Text] [Related]
19. The role of biopsy pathology, quantitative nuclear morphometry, and biomarkers in the preoperative prediction of prostate cancer staging and prognosis.
Veltri RW; O'Dowd GJ; Orozco R; Miller MC
Semin Urol Oncol; 1998 Aug; 16(3):106-17. PubMed ID: 9741414
[TBL] [Abstract][Full Text] [Related]
20. The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy?
Gingrich JR; Paulson DF
Surg Oncol Clin N Am; 1995 Apr; 4(2):335-44. PubMed ID: 7540939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
